Q-omics provides the consensus-scored UBE2FP1 profile across patient tissues and cancer cell-line models. UBE2FP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBE2FP1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, UBE2FP1 RNA expression shows 18,341 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where UBE2FP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2FP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2FP1 survival associations across molecular data types. UBE2FP1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2FP1 RNA expression–survival associations across cancer types. High UBE2FP1 expression shows unfavorable associations in ACC, KIRC, LGG and SARC, but favorable associations in CESC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBE2FP1 RNA expression.
This table summarizes UBE2FP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2FP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2FP1 shows lower tumor expression in COAD, THCA, KICH, LUAD and LUSC and higher tumor expression in KIRC. The COAD box plot shows higher UBE2FP1 RNA expression in normal versus tumor tissue (log2 FC = −1.658, t-test p < 0.001).
This table shows molecular features associated with UBE2FP1 in patient tissues and cancer cell lines. In patient samples, UBE2FP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
